Enthusiasm for the technique of percutaneous transluminal coronary angioplasty has been tempered by the realisation that 25-50% of patients have a recurrence of their symptoms in 3-6 months because of restenosis at the site of the original atheromatous lesion.' This is due not to local thrombosis or to the reaccumulation of atheroma but to a rapid growth of vascular smooth muscle cells, both within the intima and migrating from the media, which produces a new lesion known as fibrocellular intimal hyperplasia (FCIH) .' There is probably some degree of FCIH in all patients after angioplasty; and its rate of development and final quantity determine the recurrence of angina. FCIH is not unique to the vessel injured by a balloon catheter: intimal hyperplasia is a feature of the "onion skin" lesion of malignant hypertension and systemic sclerosis, the plexiform lesion in the pulmonary arterioles in pulmonary hypertension, and late vein graft occlusion.3 More recently intimal hyperplasia has been identified as the cause of the diffuse vascular disease which occurs after cardiac transplantation4 and it is the main cause of graft failure after 5 years. The vessel wall seems to have a single response to various insults on the endothelium, media, and adventitia. These insults include chronic immunological injury, sustained pressure increases, rheological changes, or direct physical distension.
Animal models There has been considerable debate about the relevance of established animal models of FCIH to the clinical problems, particularly to restenosis after angioplasty.5 In some species-for example, the rat-the normal intima consists of only a layer of endothelium and so the vascular smooth muscle cells in FCIH must be derived from the media, while in others, such as humans and the pig, the intima is much more substantial and does contain vascular smooth muscle cells. The 
